Medtronic plc
At today's price, Medtronic plc (MDT) is priced for +4.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Medtronic is one of the largest medical-device companies in the world, spread across Cardiovascular (about 38% of revenue), Neuroscience (28%), Medical-Surgical, and the diabetes business it just partly spun out through the MiniMed IPO. Fiscal 2026 delivered $36.4 billion in revenue, up 8.4% reported, its fastest annual growth in a decade. The balance sheet underwrites a 48-year dividend-increase streak. The company carries net debt near $17 billion at about 2.6 times operating income with inte
Is MDT overvalued? See what's priced in →
2,178 institutional managers reported holding MDT in 13F filings for the quarter ended 2026-03-31. Together they hold about 81% of the company; the top 10 hold 37%. 140 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 18.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (1.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MDT has cut its share count 4.6% over the past five years, spending $9.60B on repurchases. It pays a dividend, and has paid one every year in our records (12 and counting), raised 11 years straight; the current rate is $2.84 a share annually. Cash returned over the past three years: $10.89B in dividends and $6.41B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MDT over the trailing three years: 2025: 2 buys totaling $463k. 26 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MDT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-03-02 | +0.3% | +8.5% |
| 2023-09-01 | +2.5% | -11.7% |
| 2023-12-01 | +4.3% | +9.6% |
| 2024-02-28 | +1.8% | -3.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MDT's latest 8-K filings: 2026-06-03 (items 2.02, 9.01); 2026-05-18 (items 5.02, 9.01); 2026-04-27 (items 7.01, 9.01); 2026-03-24 (items 7.01); 2026-02-17 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.